The Priority Review

Category

Approvals

Decisions by the FDA and other regulators on new drugs, biologics and devices.

58 stories ยท page 4 of 5

Stories

  1. FDA approves first-of-its-kind chronic hepatitis B treatment

    The FDA approved Hibsago (bepirovirsen) injection for adults without cirrhosis who have been on antiviral therapy for at least six months and have HBsAg levels of 3,000 IU/mL or less. The approval includes the Roche Elecsys HBsAg II quant II RxDx assay as a companion diagnostic.

  2. FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer

    The FDA granted accelerated approval to dostarlimab (Jemperli, GSK) on October 19, 2026 for Stage II/III locally advanced rectal cancer that is MSI-H or dMMR. The FDA said the AZUR-1 trial of 154 patients reported a 47% sustained clinical complete response at 12 months per independent central review.

  3. FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer

    On October 19, 2026 the FDA granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer that is microsatellite instability high or mismatch repair deficient. The approval was based on AZUR-1, a single-arm trial of 154 patients that reported a 47% sustained clinical complete response at 12 months per independent central review.

  4. FDA approves Brytly, a nonprescription eye drop for eye redness

    The FDA approved Brytly, apraclonidine ophthalmic solution 0.125%, for relief of eye redness due to minor irritations. The approval is the first nonprescription eye drop containing apraclonidine and is available to adults and children 12 years of age and older.

  5. CHMP recommends marketing authorization for Kizfizo

    The Committee for Medicinal Products for Human Use adopted a positive opinion on 15 October 2026, recommending a marketing authorization for Kizfizo, a 40 mg/ml oral suspension of temozolomide, for newly diagnosed glioblastoma multiforme in adults and for recurrent or progressing malignant glioma in adults and children from the age of one year. The applicant is Orphelia Pharma and the product is designated an orphan medicine.

  6. CHMP adopts positive opinion on Yuviwel for achondroplasia

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending marketing authorization for Yuviwel (navepegritide) for children 2 years and older with achondroplasia. The opinion notes that Yuviwel improves annualised growth velocity by 1.49 cm versus placebo in a 52-week trial.

  7. CHMP recommends marketing authorization for Neuzafy

    On 15 October 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for Neuzafy, a filgrastim biosimilar. The applicant is CuraTeQ Biologics (Malta) Limited and Neuzafy will be available as 30 MU/0.5 ml and 48 MU/0.5 ml solutions for injection/infusion.

  8. CHMP adopts positive opinion on Fovlussea

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending a marketing authorization for Fovlussea, a ranibizumab biosimilar for several retinal conditions. The applicant is Accord Healthcare S.L.U., and the product will be available as a 10 mg/ml solution for injection.

  9. EMA recommends authorization of Rasonque for metastatic pancreatic cancer

    EMA's CHMP has recommended granting a marketing authorization for Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior treatment. The recommendation follows a phased review that shortened assessment to less than 150 days, with Rasonque showing a median overall survival of 12.4 months versus 6.7 months for chemotherapy in a phase 3 study of 500 patients.

  10. CHMP adopts positive opinion on Rasonque for metastatic pancreatic cancer

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending marketing authorization for Rasonque, a daraxonrasib monotherapy for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The product will be available as 100 mg and 150 mg film-coated tablets and is designated as an orphan medicine.

  11. FDA expands Anktiva indication to high-grade papillary bladder cancer

    On October 14, 2026, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) with BCG for BCG-unresponsive non-muscle invasive bladder cancer with high-grade papillary-only tumors. The agency extrapolated from earlier data in patients with carcinoma in situ.

  12. FDA approves expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive NMIBC

    On October 14, 2026, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer, adding high-grade papillary-only tumors to the prior indication for carcinoma in situ. The approval is based on efficacy data from Cohort A of QUILT-3.032, which showed a 62% complete response rate (95% CI: 51, 73).